Imcivree

Setmelanotide, the active ingredient in Imcivree, is a melanocortin receptor agonist presented as a 1 mg/mL subcutaneous injection solution for subcutaneous use. It treats obesity associated with rare genetic deficiencies, including POMC, PCSK1, LEPR, Bardet‑Biedl and Alström syndromes.

GNH USA supplies Imcivree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to global quality standards and provides cold‑chain logistics for biologic products, ensuring product integrity from manufacturing to end‑user. GNH USA also offers regulatory support and documentation to facilitate import clearance across multiple regions.

Imcivree is indicated for obesity linked to specific genetic pathways that affect appetite regulation.

Obesity due to POMC deficiency: reduces appetite and supports weight loss in patients with confirmed POMC deficiency. Obesity due to PCSK1 deficiency: improves energy balance and promotes weight reduction in individuals with PCSK1‑related obesity. Obesity due to LEPR deficiency: lowers hunger signals and aids weight management in patients lacking functional leptin receptors. Obesity associated with Bardet‑Biedl syndrome: helps achieve clinically meaningful weight loss in this rare genetic disorder. Obesity associated with Alström syndrome: contributes to reduced body weight in patients with Alström‑related obesity.

Common Side Effects: - Injection site erythema or pain - Nausea or vomiting - Headache - Constipation or abdominal discomfort - Hyperpigmentation of skin or mucous membranes - Fatigue or dry mouth

Serious or Rare Side Effects: - Severe hyperpigmentation extending beyond injection site - Hypersensitivity reactions, including anaphylaxis - Cardiovascular events such as elevated blood pressure or tachycardia - Psychiatric symptoms, including suicidal ideation or mood changes

Imcivree requires careful monitoring in several clinical situations.

Pregnancy: safety not established; use only if potential benefit justifies the risk. Breastfeeding: unknown effects; consider discontinuation. Renal impairment: monitor renal function as clearance may be reduced. Cardiovascular disease: observe blood pressure and heart rate during therapy. Hypersensitivity: discontinue immediately if severe allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Setmelanotide has a limited interaction profile, but caution is advised with certain co‑medications.

Major Interactions (Avoid): - Concurrent use of other MC4R agonists: may produce additive pharmacodynamic effects. - Strong CYP450 inhibitors (theoretical): could increase systemic exposure, although metabolism is minimal.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: blood pressure changes may require dose adjustment. - Drugs affecting glucose metabolism: monitor glycemic control as weight loss can alter insulin sensitivity. - Other injectable biologics: may increase risk of injection‑site reactions.